Methods for determining sodium-proton-exchanger ligand efficiency
View Patent ↗The present invention relates to methods for determining the in vivo efficiency of a sodium-proton-exchanger (NHE) ion channel ligand comprising the steps of: (a) contacting a cell expressing a sodium-proton-exchanger (NHE) ion channel in vitro with either (i) plasma of an animal and the ion channel ligand or (ii)) the plasma of an animal which has been administered the ion channel ligand; (b) determining the effect of the ion channel ligand on the cell; c) determining ion channel ligand availability by comparing the ligand concentration in the plasma to the concentration of ligand administered; and d) correlating the effect of the ion channel ligand on the cell with the ligand availability to determine the in vivo efficiency of the ligand.
1. A method for determining the in vivo efficiency of a sodium-proton-exchanger (NHE) ion channel ligand comprising the steps of:
a) contacting a cell expressing a sodium-proton-exchanger (NHE) ion channel in vitro with either
i) plasma of an animal and the ion channel ligand, or
ii) the plasma of an animal which has been administered the ion channel ligand;
b) determining the effect of the ion channel ligand on the cell
c) determining ion channel ligand availability by comparing the ligand concentration in the plasma to the concentration of ligand administered; and
d) correlating the effect of the ion channel ligand on the cell with the ligand availability to determine the in vivo efficiency of the ligand.
2. The method of claim 1 , wherein the NHE is NHE1, NHE2, NHE3 or NHE5.
3. The method of claim 1 , wherein the ion channel ligand is an agonist or an antagonist.
4. The method of claim 1 , wherein the cell is a cell line.
5. The method of claim 1 , wherein the animal is a vertebrate.
6. The method of claim 1 , wherein the animal is a human.
7. The method of claim 1 , wherein the effect is an alteration of a pH-value.
8. The method of claim 7 , wherein the effect is an alteration of the intracellular pH-value.
9. The method of claim 1 , wherein the effect is determined by fluorescence.
10. The method of claim 1 , wherein the NHE ligand has been administered the animal, wherein the animal is to a non-human animal.
11. The method of claim 1 , wherein the method is used for screening for a medicament for treating a disease involving ion channel dysfunction.
12. The method of claim 1 , wherein the method is used for screening for a medicament for preventing and/or treating a cardiovascular disease or cancer.
13. The method of claim 4 , wherein the cell line is a mammalian cell line.
14. The method of claim 13 , wherein the cell line is a human cell line.
15. The method of claim 13 , wherein the cell line is a mouse cell line.
16. The method of claim 15 , wherein the cell line is a mouse LTK cell line.
17. The method of claim 5 , wherein the vertebrate is a mammal.
18. The method of claim 17 , wherein the mammal is selected from the group consisting of rat, mouse, rabbit, guinea pig and cat.